Cited 0 times in
Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:05:52Z | - |
dc.date.available | 2023-06-02T01:05:52Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194650 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | S. Banerjee | - |
dc.contributor.googleauthor | M. Imbimbo | - |
dc.contributor.googleauthor | P. Roxburgh | - |
dc.contributor.googleauthor | J-W. Kim | - |
dc.contributor.googleauthor | M.H. Kim | - |
dc.contributor.googleauthor | R. Plummer | - |
dc.contributor.googleauthor | S. Stemmer | - |
dc.contributor.googleauthor | B. You | - |
dc.contributor.googleauthor | M. Ferguson | - |
dc.contributor.googleauthor | R.T. Penson | - |
dc.contributor.googleauthor | D. O'Malley | - |
dc.contributor.googleauthor | K. Meyer | - |
dc.contributor.googleauthor | H. Gao | - |
dc.contributor.googleauthor | H. Angell | - |
dc.contributor.googleauthor | A. Tablante Nunes | - |
dc.contributor.googleauthor | S. Domchek | - |
dc.contributor.googleauthor | Y. Drew | - |
dc.identifier.doi | 10.1016/j.annonc.2022.07.657 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S092375342202508X | - |
dc.citation.volume | 33 | - |
dc.citation.number | Supplement 7 | - |
dc.citation.startPage | S788 | - |
dc.citation.endPage | S789 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Supplement 7) : S788-S789, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.